Safety of blood-pressure drug reviewed

Health Canada is reviewing the safety of the blood-pressure drug Rasilez after its manufacturer halted a large study that showed the medication could have adverse effects when combined with some other prescription drugs.

Health Canada is reviewing the safety of the blood-pressure drug Rasilez after its manufacturer halted a large study that showed the medication could have adverse effects when combined with some other prescription drugs.

The ALTITUDE study was trying to determine whether Rasilez (aliskiren) could reduce the risk of cardiovascular and kidney problems in patients with diabetes and renal impairment when taken with other blood pressure-lowering drugs.

Novartis terminated the multinational clinical trial after interim data suggested Rasilez was unlikely to benefit those patients and could potentially cause harm.

Specifically, when used in combination with drugs known as ACE-inhibitors or angiotensin receptor blockers (ARBs), Rasilez was associated with an increased risk of non-fatal stroke, kidney complications, high levels of potassium in the blood and low blood pressure.

Rasilez is currently authorized in Canada for use either alone or in combination with other drugs, including ACE-inhibitors and ARBs to control high blood pressure.

Health Canada said it is evaluating available safety data, including information from Novartis and international regulatory bodies, to determine if prescribing changes are needed.

As a precautionary measure, Novartis has said it is no longer promoting Rasilez use in combination with an ACE-inhibitor or ARB drugs.

Consumers taking Rasilez either alone or in combination with other blood pressure-reducing drugs who have questions or concerns should talk to their health professional.

They should not stop treatment without consulting their health-care professional.

If untreated, high blood pressure can cause serious health effects over time.

The ALTITUDE study involved 8,606 participants from 36 countries, including 329 in Canada. Participants should contact their study site for guidance on medication and should not stop treatment until they have seen their physician, Health Canada said.

Online:

Novartis, www.novartis.com/

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

107 new cases of COVID-19 in Alberta, 5 additional deaths

More than 1,000 cases in Alberta total

Red Deer trucker ‘nervous’ on front lines of COVID-19 fight

Patrick O’Connor is just looking for some help for the common man.… Continue reading

Gardening for food during COVID-19

“Gardening is easy, and there’s always Google”

WATCH: Update from Prime Minister Trudeau

April 3 briefing from Ottawa

Alberta Health Services provides COVID-19 prevention tips

Alberta Health Services has a number of recommendations for people amid the… Continue reading

Alberta government website has latest COVID-19 statistics

Red Deer Advocate readers can stay up to date on the COVID-19… Continue reading

Policing the pandemic will put marginalized communities at risk, advocates say

Policing the pandemic will put marginalized communities at risk, advocates say

Maskwacis police looking for suspect after shooting

Police are seeking assistance to locate a man wanted for discharging a firearm with intent.

WATCH: Town of Blackfalds released COVID-19 update video

Changes include Blackfalds Transfer Station hours of operation, BOLT schedules and staffing updates.

City of Lacombe announces BOLT Transit service change due to COVID-19

BOLT Transit is suspending its evening express route leaving from Red Deer at 8:24 p.m.

Lacombe Police recover stolen vehicles from Emily Crescent address

Investigation led police to an address where 2017 Audi Q7 and a 2019 Ford F150 were recovered

Projections show between 3,000 and 15,000 could die from COVID-19 in Ontario

TORONTO — The steps the Ontario government has taken so far to… Continue reading

Most Read